26.06.2018 curasan AG  DE0005494538

DGAP-News: curasan signs exclusive Cooperation for Hemostatic Product stypro(R) in Germany


 
DGAP-News: curasan AG / Key word(s): Alliance curasan signs exclusive Cooperation for Hemostatic Product stypro(R) in Germany 26.06.2018 / 09:43 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- curasan signs exclusive Cooperation for Hemostatic Product stypro(R) in Germany - Exclusive Distribution Agreement for Hemostatic Sponge stypro(R) - Extensive Access to German Hospital Market Kleinostheim, 26 June 2018 - curasan AG, Germany, a leading specialist for medical products in the field of orthobiologics, has signed an exclusive distribution agreement with P.J. Dahlhausen & Co. GmbH. Starting beginning of July the company with headquarters in Cologne, Germany, is going to include curasan's hemostatic product stypro(R) in their sales portfolio and, as a first step, place it on the German market. "This cooperation with Dahlhausen underlines our strategy to continuously shift local sales activities at the point of sales, especially in hospitals, to specialists on site", explains Michael Schlenk, CEO of curasan AG. "With Dahlhausen we found a partner who is exceptionally well established in the hospital market and who can ensure a high presence at our target groups with more than 40 people in his hospital sales force." "As one of the leading full-range suppliers of clinical accessories for hospitals throughout Germany we are increasingly extending our product line also for the orthopedics and traumatology sector", says Ulrich Dahlhausen, General Manager of the family business. "Therefore, the hemostatic product stypro(R) is an ideal supplement for our portfolio." stypro(R) is a highly porous sponge made of porcine gelatin which supports the blood clotting process in a physiological way. As P.J. Dahlhausen & Co. GmbH is globally active, the two companies will consider at a later point if the cooperation can be extended to other markets as well. Your contact at curasan AG: Andrea Weidner Head of Investor Relations & Corporate Communications +49 6027 40 900-51 andrea.weidner@curasan.com About curasan AG: curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan. curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in Wake Forest, near Raleigh, N.C., USA. curasan's innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. curasan AG is a public company listed in the General Standard at the Frankfurt Stock Exchange. About P.J. Dahlhausen & Co. GmbH The company founded in 1854 develops, manufactures and markets high quality medical products with more than 500 employees within the group exporting and importing on a global scale. The company has positioned itself as a partner along the entire supply and value chain. As Europe's largest full-range provider of clinical supplies, the range of products comprising more than 3,000 different quality products systematically answers every need in anesthesiology, surgery and patient care. Besides their headquarters in Cologne, Dahlhausen maintains a newly built production and logistics center in Halberstadt, Sachsen-Anhalt, with constantly expanding warehouse and production facilities. At this site, the company is setting new standards for the assembly and availability of medical devices throughout Germany. --------------------------------------------------------------------------- 26.06.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: curasan AG Lindigstraße 4 63801 Kleinostheim Germany Phone: 06027/40 900 0 Fax: 06027/40 900 29 E-mail: info@curasan.de Internet: www.curasan.de ISIN: DE0005494538 WKN: 549453 Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 697073 26.06.2018


Die wichtigsten Finanzdaten auf einen Blick
  2012 2013 2014 2015 2016 2017 2018 2019e
Umsatzerlöse1 3,23 5,82 5,76 5,97 6,93 6,80 5,84 6,40
EBITDA1,2 -2,97 -1,64 -1,12 2,13 -2,14 -2,22 -3,84 -3,00
EBITDA-Marge3 -91,95 -28,18 -19,44 35,68 -30,88 -32,65 -65,75 -46,88
EBIT1,4 -3,32 -2,14 -1,83 1,33 -2,66 -2,84 -4,78 -2,80
EBIT-Marge5 -102,79 -36,77 -31,77 22,28 -38,38 -41,76 -81,85 -43,75
Jahresüberschuss1 -3,47 -2,14 -1,83 1,33 -2,09 -4,00 -5,38 -2,50
Netto-Marge6 -107,43 -36,77 -31,77 22,28 -30,16 -58,82 -92,12 -39,06
Cashflow1,7 -2,72 -1,85 -0,37 2,15 -2,11 -2,55 -4,34 0,00
Ergebnis je Aktie8 -1,53 -0,90 -0,72 0.45 -0,63 -0,99 -0,99 -0,33
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2018 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Hinrik J. Schröder

INVESTOR-INFORMATIONEN
©boersengefluester.de
Curasan
WKN Kurs in € Einschätzung Börsenwert in Mio. €
549453 0,470 Verkaufen 4,26
KGV 2020e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 15,55 0,000 0,00
KBV KCV KUV EV/EBITDA
0,57 - 0,73 -1,204
Dividende '18 in € Dividende '19e in € Div.-Rendite '18
in %
Hauptversammlung
0,00 0,00 0,00 26.06.2019
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
23.05.2019 22.08.2019 21.11.2019 13.05.2019
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
14,63% -17,54% -7,84% -48,91%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu curasan AG  ISIN: DE0005494538 können Sie bei DGAP abrufen

Gesundheit , 549453 , CUR , XETR:CUR